News headlines about Mallinckrodt PLC (NYSE:MNK) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Mallinckrodt PLC earned a news impact score of 0.11 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 44.4577706024664 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the headlines that may have impacted Accern’s scoring:
- Mallinckrodt (MNK) Presents Health Economic Data on OFIRMEV Injection at ASRA Meeting – StreetInsider.com (streetinsider.com)
- Mallinckrodt plc Presents Health Economic Data on OFIRMEV® (acet – KAIT Jonesboro, AR – Region 8 News, weather, sports (kait8.com)
- Mallinckrodt To Present At The BMO Prescriptions for Success Healthcare Conference (finance.yahoo.com)
- Why Mallinckrodt Cratered – Mallinckrodt PLC (NYSE:MNK … – Seeking Alpha (seekingalpha.com)
Several equities research analysts have recently weighed in on the stock. Canaccord Genuity set a $24.00 target price on shares of Mallinckrodt PLC and gave the company a “hold” rating in a research note on Tuesday, November 14th. UBS AG downgraded shares of Mallinckrodt PLC from a “buy” rating to a “neutral” rating and set a $24.00 target price on the stock. in a research note on Monday, November 13th. Stifel Nicolaus reduced their target price on shares of Mallinckrodt PLC from $70.00 to $50.00 and set a “buy” rating on the stock in a research note on Wednesday, November 8th. Morgan Stanley reduced their target price on shares of Mallinckrodt PLC from $40.00 to $27.00 and set an “equal weight” rating on the stock in a research note on Wednesday, November 8th. Finally, BMO Capital Markets reduced their target price on shares of Mallinckrodt PLC to $38.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 8th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have issued a buy rating to the stock. Mallinckrodt PLC presently has an average rating of “Hold” and a consensus target price of $48.14.
Shares of Mallinckrodt PLC (NYSE:MNK) traded down $0.57 during trading on Monday, reaching $21.81. 4,342,098 shares of the company’s stock traded hands, compared to its average volume of 2,529,379. The company has a current ratio of 1.38, a quick ratio of 1.05 and a debt-to-equity ratio of 1.08. Mallinckrodt PLC has a one year low of $19.00 and a one year high of $58.09. The company has a market cap of $2,126.21, a PE ratio of 3.02, a price-to-earnings-growth ratio of 0.32 and a beta of 1.46.
Mallinckrodt PLC (NYSE:MNK) last issued its earnings results on Tuesday, November 7th. The company reported $1.97 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.80 by $0.17. Mallinckrodt PLC had a net margin of 11.43% and a return on equity of 14.79%. The company had revenue of $793.90 million for the quarter, compared to analysts’ expectations of $808.93 million. During the same period in the prior year, the business earned $2.04 EPS. The firm’s quarterly revenue was down 10.5% on a year-over-year basis. research analysts predict that Mallinckrodt PLC will post 7.23 earnings per share for the current year.
In other news, Director David R. Carlucci purchased 10,000 shares of the stock in a transaction dated Thursday, November 9th. The shares were acquired at an average cost of $21.83 per share, for a total transaction of $218,300.00. Following the acquisition, the director now owns 26,020 shares of the company’s stock, valued at $568,016.60. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Steven J. Romano purchased 2,000 shares of the stock in a transaction dated Monday, November 13th. The stock was purchased at an average price of $21.96 per share, for a total transaction of $43,920.00. The disclosure for this purchase can be found here. Insiders bought a total of 27,180 shares of company stock worth $610,166 over the last 90 days. Company insiders own 0.53% of the company’s stock.
TRADEMARK VIOLATION WARNING: This news story was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international trademark and copyright law. The legal version of this news story can be accessed at https://ledgergazette.com/2017/11/20/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-mallinckrodt-plc-mnk-share-price.html.
Mallinckrodt PLC Company Profile
Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs.
Receive News & Ratings for Mallinckrodt PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt PLC and related companies with MarketBeat.com's FREE daily email newsletter.